Isis Pharmaceuticals has had an enormous run of late. Is this drugmaker still a buy?
Pfizer may be about to break up. Here's what investors need to know.
AbbVie Inc has agreed to pay $21 billion to acquire Pharmacyclics, Inc.
Three stock market nobles make our update for this week.
Controversial hedge fund tycoon George Soros just sold three top dividend stocks. Should you follow his lead?
Momenta shares rose by more than 10% earlier today on optimism it will overcome headwinds.
Pfizer has jumped into the promising field of cancer immunotherapy with both feet. Is this effort too little, too late for the pharma giant?
Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.
Motley Fool experts offer up insight into three intriguing small-cap biotech stocks.
Illumina gene sequencing demand could head higher thanks to President Obama's precision medicine plan.